BRAIN Biotech AG (HAM:BNN) Asset Turnover: 0.18 (As of Mar. 2026)


HAM:BNN BRAIN Biotech AG HAM:BNN
66 GF Score
Price €2.72
GF Value €2.56
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is BRAIN Biotech AG Asset Turnover?

BRAIN Biotech AG HAM:BNN -3.89% 66 Asset Turnover is 0.18 as of Mar. 2026. GuruFocus rates HAM:BNN with a GF Score™ of 66/100 and a GF Value™ of €2.56 (Fairly Valued). The stock has 2 warning signs investors should review.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. BRAIN Biotech AG's Revenue for the three months ended in Mar. 2026 was €11.48 Mil. BRAIN Biotech AG's Total Assets for the quarter that ended in Mar. 2026 was €64.78 Mil. Therefore, BRAIN Biotech AG's Asset Turnover for the quarter that ended in Mar. 2026 was 0.18.

Asset Turnover is linked to ROE % through Du Pont Formula. BRAIN Biotech AG's annualized ROE % for the quarter that ended in Mar. 2026 was 601.83%. It is also linked to ROA % through Du Pont Formula. BRAIN Biotech AG's annualized ROA % for the quarter that ended in Mar. 2026 was -21.36%.

BRAIN Biotech AG  (HAM:BNN) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

BRAIN Biotech AG's annulized ROE % for the quarter that ended in Mar. 2026 is

ROE %**(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-13.836/-2.299
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-13.836 / 45.936)*(45.936 / 64.781)*(64.781/ -2.299)
=Net Margin %*Asset Turnover*Equity Multiplier
=-30.12 %*0.7091*-28.1779
=ROA %*Equity Multiplier
=-21.36 %*-28.1779
=601.83 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

BRAIN Biotech AG's annulized ROA % for the quarter that ended in Mar. 2026 is

ROA %(Q: Mar. 2026 )
=Net Income/Total Assets
=-13.836/64.781
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-13.836 / 45.936)*(45.936 / 64.781)
=Net Margin %*Asset Turnover
=-30.12 %*0.7091
=-21.36 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.

BRAIN Biotech AG Asset Turnover Related Terms

BRAIN Biotech AG Asset Turnover Historical Data

* Premium members only.

The historical data trend for BRAIN Biotech AG's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BRAIN Biotech AG Asset Turnover Chart

BRAIN Biotech AG Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.51 0.64 0.74 0.69 0.65

BRAIN Biotech AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.18 0.16 0.18 0.18

HAM:BNN vs LIN, SHW, ECL: Asset Turnover Comparison

For the Specialty Chemicals subindustry, BRAIN Biotech AG's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BRAIN Biotech AG Asset Turnover vs Chemicals Industry

For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's Asset Turnover distribution charts can be found below:

* The bar in red indicates where BRAIN Biotech AG's Asset Turnover falls into.


HAM:BNN
66GF Score
BRAIN Biotech AG HAM:BNN
Asset Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BRAIN Biotech AG Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

BRAIN Biotech AG's Asset Turnover for the fiscal year that ended in Sep. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Sep. 2025 )/( (Total Assets (A: Sep. 2024 )+Total Assets (A: Sep. 2025 ))/ count )
=50.016/( (88.737+66.337)/ 2 )
=50.016/77.537
=0.65

BRAIN Biotech AG's Asset Turnover for the quarter that ended in Mar. 2026 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=11.484/( (66.905+62.657)/ 2 )
=11.484/64.781
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of 0.18 mean?
BRAIN Biotech AG (HAM:BNN) has a Asset Turnover of 0.18 as of Mar. 2026. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on BRAIN Biotech AG and its competitors.
Is BRAIN Biotech AG's Asset Turnover too high?
BRAIN Biotech AG's current Asset Turnover is 0.18. Overall, BRAIN Biotech AG has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BRAIN Biotech AG's Asset Turnover compare to LIN and SHW?
BRAIN Biotech AG's Asset Turnover of 0.18 can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Chemicals company?
A good Asset Turnover depends on the Chemicals industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on BRAIN Biotech AG and its competitors. BRAIN Biotech AG's current Asset Turnover is 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRAIN Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, BRAIN Biotech AG (HAM:BNN) is currently considered Fairly Valued. The stock's GF Value™ is €2.56, compared to a current price of €2.72 — trading 6.3% above its estimated fair value. The current Asset Turnover is 0.18. BRAIN Biotech AG's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For BRAIN Biotech AG (HAM:BNN), the current Asset Turnover is 0.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BRAIN Biotech AG (HAM:BNN) Overvalued in 2026?

Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued. The current stock price of €2.72 is trading 6.3% above its estimated GF Value™ of €2.56. GuruFocus considers BRAIN Biotech AG to be Fairly Valued.

Key valuation signals for HAM:BNN:

  • Asset Turnover: 0.18
  • GF Value™: €2.56 vs. price of €2.72 (6.3% above fair value)
  • GF Score™: 66/100 with 2 warning signs

No single metric tells the full story. See the HAM:BNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BRAIN Biotech AG Business Description

Other Exchanges 0RFI:UKBNN:Germany
Address Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
66GF Score

Get the complete analysis for HAM:BNN

Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.72
Price
€2.56
GF Value